Comment on: Monotherapy versus combination therapy for sepsis due to multidrug-resistant Acinetobacter baumannii: Analysis of a multicentre prospective cohort

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 11, 2014, Pages 3167-3167

  Karabay, Oguz ^a   Batirel, Ayse ^b   Balkan, Ilker Inanc ^c  

^a SAKARYA UNIVERSITY   (Turkey)

^b DR LUTFI KIRDAR KARTAL EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^c ISTANBUL UNIVERSITY   (Turkey)

Author keywords

A. baumannii; MDR; MDRAB

Indexed keywords

ANTIINFECTIVE AGENT; TIGECYCLINE;

ACINETOBACTER BAUMANNII; ANTIBIOTIC THERAPY; ANTIMICROBIAL THERAPY; COMBINATION CHEMOTHERAPY; HUMAN; INFECTION; INTERMETHOD COMPARISON; LETTER; MONOTHERAPY; MORTALITY RATE; MULTICENTER STUDY (TOPIC); MULTIDRUG RESISTANCE; NONHUMAN; SAMPLE SIZE; SEPSIS; SKIN INFECTION; SOFT TISSUE INFECTION; ACINETOBACTER INFECTIONS; DRUG EFFECTS; FEMALE; ISOLATION AND PURIFICATION; MALE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; MALE; SEPSIS;

EID: 84931831685     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku301     Document Type: Letter

References (4)

1. López-Cortés LE, Cisneros JM, Fernández-Cuenca F et al. Monotherapy versus combination therapy for sepsis due to multidrug-resistant Acinetobacter baumannii: analysis of a multicentre prospective cohort. J Antimicrob Chemother 2014; 69: 3119-26.
2. Montravers P, Bassetti M, Dupont H et al. Efficacy of tigecycline for the treatment of complicated skin and soft-tissue infections in real-life clinical practice from five European observational studies. J Antimicrob Chemother 2013; 68 Suppl 2: ii15-24.
3. Reid GE, Grim SA, Aldeza CA et al. Rapid development of Acinetobacter baumannii resistance to tigecycline. Pharmacotherapy 2007; 27: 1198-201.
4. Curcio D. Treatment of recurrent urosepsis with tigecycline: a pharmacological perspective. J Clin Microbiol 2008; 46: 1892-3.